Document:

Exhibit 10.20

 

FOURTH AMENDMENT, WAIVER AND CONSENT

 

This Fourth Amendment,
Waiver and Consent (“Fourth Consent”) is made and entered into as of May ___, 2016, by and among Accelerated Pharma,
Inc., a Delaware corporation (the “Company”), and the parties identified on the signature page hereto (each a “Purchaser”
and collectively, “Purchasers”). Capitalized terms used but not defined herein will have the meanings assigned to
them in the Securities Purchase Agreements and Transaction Documents (as defined below). Capitalized terms defined herein shall
be incorporated in the Transaction Documents, as appropriate.

 

WHEREAS, the Company
and Purchasers identified on Schedule A entered into Securities Purchase Agreements (“Securities Purchase Agreements”)
and other Transaction Documents (collectively, “Transaction Documents”) dated as of December 23, 2014, May 8, 2015,
June 11, 2015, November 6, 2015, and April 20, 2016; and

 

WHEREAS, the Transaction
Documents were previously amended and certain consents and waivers were granted pursuant to a certain Amendment, Waiver and Consent
entered into as of May 8, 2015 and as further amended on November 6, 2015 pursuant to a Second Amendment, Waiver and Consent and
as further amended on April 20, 2016 pursuant to a Third Amendment, Waiver and Consent; and

 

WHEREAS, the Company
issued to the Purchasers Secured Convertible Notes (“Notes”) and Warrants (the “Warrants”); and

 

WHEREAS, the Company
wishes to amend the definition of Qualified Offering as it appears in the Securities Purchase Agreements and Transaction Documents;
and

 

WHEREAS, the Company
and Purchasers agree to the following amendments, waivers, and consents, which amendments, waivers and consents shall be effective,
the approval of a Majority in Interest which shall be binding on all Purchasers (“Effective Date”).

 

NOW, THEREFORE, the
Company and Purchasers hereby agree as follows:

 

1.          The
definition of “Qualified Offering” in Section 1.1 of the Securities Purchase Agreements is deleted and replaced with
the following:

 

““Qualified
Offering” means the occurrence of an offering of the Company’s Common Stock which closes in one or more closings
in connection with which the Company receives not less than $5,000,000 of gross cash proceeds from the sale of Common Stock on
or before November 15, 2016.”

 

2.          The
undersigned represents to the Company that it is the holder of the Notes and Warrants in the amounts set forth on Schedule A
hereto, it has not sold, transferred or otherwise assigned any of the Notes and Warrants and it has the authority to enter into
and deliver this Consent.

 

3.          The
Company represents that Schedule A hereto identifies all of the holders and sets forth the amounts as of the date herein
of all of the securities issued or issuable pursuant to the Securities Purchase Agreements and that the Transaction Documents have
not been previously amended nor any waiver of any term thereof granted by any party thereto other than as set forth in the Amendment
Waiver and Consent, the Second Amendment, Waiver and Consent, the Third Amendment, Waiver and Consent and this Fourth Consent.

 

    	 	1	 

     

    

 

4.          This
Fourth Consent may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute
one and the same instrument. This Fourth Consent may be signed and delivered by facsimile or electronically and such facsimile
or electronically signed and delivered Fourth Consent shall be enforceable.

 

5.          This
Fourth Consent shall be included in the definition of Transaction Documents as such term is defined in the Securities Purchase
Agreements.

 

6.          Sections
5.4, 5.5, 5.12 and 5.21 of the Securities Purchase Agreements are incorporated herein by reference.

 

7.          Except
as expressly set forth herein, this Fourth Consent shall not be deemed to be a waiver, amendment or modification of any provisions
of the Transaction Documents or of any right, power or remedy of the Purchaser, or constitute a waiver of any provision
of the Transaction Documents (except to the extent herein set forth), or any other document, instrument and/or agreement executed
or delivered in connection therewith and any other agreement to which the Purchaser may be parties to, in each case whether arising
before or after the date hereof or as a result of performance hereunder or thereunder. Except as set forth herein, the Purchaser
reserves all rights, remedies, powers, or privileges available under the Transaction Documents and any other agreement to
which the Purchaser may be parties to, at law or otherwise. This Fourth Consent shall not constitute a novation or satisfaction
and accord of the Transaction Documents or any other document, instrument and/or agreement executed or delivered in connection
therewith and any other agreement to which the Purchaser may be a party to.

 

(Signatures to follow)

 

    	 	2	 

     

    

 

IN WITNESS WHEREOF, the Company and the
undersigned Purchasers have caused this Fourth Consent to be executed as of the date first written above.

 

	 	ACCELERATED PHARMA, INC.
	 	the “Company”
	 	 	 
	 	By:	 

 

“PRIOR
PURCHASER”

 

Name of Prior Purchaser:
____________________________________________________________________________

 

Signature of Authorized Signatory of
Prior Purchaser: ______________________________________________________

 

Name of Authorized Signatory: _______________________________________________________________________

 

Title of Authorized Signatory: ________________________________________________________________________

 

    	 	3Exhibit 10.21

 

FIFTH AMENDMENT, WAIVER AND CONSENT

 

This Fifth Amendment,
Waiver and Consent (“Fifth Consent”) is made and entered into as of July 15 , 2016, by and among Accelerated Pharma,
Inc., a Delaware corporation (the “Company”), and the parties identified on the signature page hereto (each a “Purchaser”
and collectively, “Purchasers”). Capitalized terms used but not defined herein will have the meanings assigned to them
in the Securities Purchase Agreements and Transaction Documents (as defined below). Capitalized terms defined herein shall be incorporated
in the Transaction Documents, as appropriate.

 

WHEREAS, the Company
and Purchasers identified on Schedule A entered into Securities Purchase Agreements (“Securities Purchase Agreements”)
and other Transaction Documents (collectively, “Transaction Documents”) dated as of December 23, 2014, May 8, 2015,
June 11, 2015, November 6, 2015, April 20, 2016, April 22, 2016, May 9, 2016 and May 27, 2016; and

 

WHEREAS, the Transaction
Documents were previously amended and certain consents and waivers were granted pursuant to a certain Amendment, Waiver and Consent
entered into as of May 8, 2015 and as further amended on November 6, 2015 pursuant to a Second Amendment, Waiver and Consent and
as further amended on April 20, 2016 pursuant to a Third Amendment, Waiver and Consent and as further amended on May 9, 2016 pursuant
to a Fourth Amendment, Waiver and Consent; and

 

WHEREAS, the Company
issued to the Purchasers Secured Convertible Notes (“Notes”) and Warrants (the “Warrants”); and

 

WHEREAS, the Company
wishes to amend the definition of Termination Date as it is employed in the Securities Purchase Agreements and Transaction Documents
to allow additional Closings for the balance of the maximum allowed Subscription Amount to occur until September 1, 2016 instead
of June 30, 2016 as well as to increase the maximum allowed Subscription Amount from $1,500,000 to up to $2,000,000; and

 

WHEREAS, the Company
and Purchasers agree to the following amendments, waivers, and consents, which amendments, waivers and consents shall be effective,
the approval of a Majority in Interest which shall be binding on all Purchasers (“Effective Date”).

 

NOW, THEREFORE, the
Company and Purchasers hereby agree as follows:

 

1.          The
term “Termination Date” and the maximum allowed Subscription Amount as both are defined in Section 2.1 of the Securities
Purchase Agreements shall mean September 1, 2016 and $2,000,000, respectively.

 

2.          The
undersigned represents to the Company that it is the holder of the Notes and Warrants in the amounts set forth on Schedule A
hereto, it has not sold, transferred or otherwise assigned any of the Notes and Warrants and it has the authority to enter into
and deliver this Consent.

 

3.          The
Company represents that Schedule A hereto identifies all of the holders and sets forth the amounts as of the date herein
of all of the securities issued or issuable pursuant to the Securities Purchase Agreements and that the Transaction Documents have
not been previously amended nor any waiver of any term thereof granted by any party thereto other than as set forth in the Amendment
Waiver and Consent, the Second Amendment, Waiver and Consent, the Third Amendment, Waiver and Consent, the Fourth Amendment, Waiver
and Consent and this Fifth Consent.

 

    	 	1	 

     

    

 

 

4.          This
Fifth Consent may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute
one and the same instrument. This Fifth Consent may be signed and delivered by facsimile or electronically and such facsimile or
electronically signed and delivered Fifth Consent shall be enforceable.

 

5.          This
Fifth Consent shall be included in the definition of Transaction Documents as such term is defined in the Securities Purchase Agreements.

 

6.          Sections
5.4, 5.5, 5.12 and 5.21 of the Securities Purchase Agreements are incorporated herein by reference.

 

7.          Except
as expressly set forth herein, this Fifth Consent shall not be deemed to be a waiver, amendment or modification of any provisions
of the Transaction Documents or of any right, power or remedy of the Purchaser, or constitute a waiver of any provision
of the Transaction Documents (except to the extent herein set forth), or any other document, instrument and/or agreement executed
or delivered in connection therewith and any other agreement to which the Purchaser may be parties to, in each case whether arising
before or after the date hereof or as a result of performance hereunder or thereunder. Except as set forth herein, the Purchaser
reserves all rights, remedies, powers, or privileges available under the Transaction Documents and any other agreement to
which the Purchaser may be parties to, at law or otherwise. This Fifth Consent shall not constitute a novation or satisfaction
and accord of the Transaction Documents or any other document, instrument and/or agreement executed or delivered in connection
therewith and any other agreement to which the Purchaser may be a party to.

 

(Signatures to follow)

 

    	 	2	 

     

    

 

IN WITNESS WHEREOF, the Company and the
undersigned Purchasers have caused this Fifth Consent to be executed as of the date first written above.

 

	 	ACCELERATED PHARMA, INC.
	 	the “Company”
	 	 	 
	 	By:	 

 

“PRIOR
PURCHASER”

 

Name of Prior Purchaser:
____________________________________________________________________________

 

Signature of Authorized Signatory of
Prior Purchaser: ______________________________________________________

 

Name of Authorized Signatory: _______________________________________________________________________

 

Title of Authorized Signatory: ________________________________________________________________________

 

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]